Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis
The high diagnostic performance of somatostatin receptor positron emission tomography with computed tomography (PET/CT) in neuroendocrine tumours (NETs) was demonstrated by several articles. However, only some studies evaluated the detection rate (DR) of this imaging method in patients with metastatic NETs and unknown primary tumours (CUP-NETs). Therefore, we aimed to perform a meta-analysis to add evidence-based data in this setting.
A comprehensive computer literature search of studies listed in PubMed/MEDLINE, EMBASE, and Cochrane library databases through December 2018 and regarding the use of somatostatin receptor PET/CT in patients with CUP-NETs was carried out. Pooled DR of CUP-NETs by using somatostatin receptor PET/CT was calculated. A pooled analysis evaluating the percentage of change of management by using somatostatin receptor PET/CT in these patients was also performed.
Twelve studies on the use of somatostatin receptor PET/CT in detecting CUP-NETs in 383 metastatic patients were included. The meta-analysis of all these studies provided the following DR on a per patient-based analysis: 56% (95% confidence interval (95% CI): 48–63%). Moderate heterogeneity among the selected studies was found (I2 = 50%), whereas a significant publication bias was excluded by Egger’s test (p = 0.45). The most common primary tumour sites were the bowel and the pancreas. A change of management by using somatostatin receptor PET/CT was demonstrated in 20% (95% CI: 10–33%) of patients with CUP-NET.
Somatostatin receptor PET/CT is very useful in detecting CUP-NETs in patients with metastatic disease. More studies on the change of management by using this imaging method in this setting are needed.
KeywordsPET Somatostatin Neuroendocrine Unknown primary CUP-NET.
We thank all the staff of the Clinical Trial Unit of Ente Ospedaliero Cantonale for their support. The Clinical Trail Unit of Ente Ospedaliero Cantonale was in charge of literature search, statistical analysis and manuscript writing.
This study was performed through a funded activity of the Clinical Trial Unit of Ente Ospedaliero Cantonale.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 4.M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska, W.J.G. Oyen, A. Chiti, F. Giammarile, A. Sundin, S. Fanti, Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur. J. Nucl. Med. Mol. imaging 44(9), 1588–1601 (2017). https://doi.org/10.1007/s00259-017-3728-y Google Scholar
- 8.M. Barrio, J. Czernin, S. Fanti, V. Ambrosini, I. Binse, L. Du, M. Eiber, K. Herrmann, W.P. Fendler, The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J. Nucl. Med. 58(5), 756–761 (2017). https://doi.org/10.2967/jnumed.116.185587 Google Scholar
- 9.S.A. Deppen, J. Blume, A.J. Bobbey, C. Shah, M.M. Graham, P. Lee, D. Delbeke, R.C. Walker, 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 57(6), 872–878 (2016). https://doi.org/10.2967/jnumed.115.165803 Google Scholar
- 11.G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80–87 (2012). https://doi.org/10.1007/s12020-012-9631-1 Google Scholar
- 13.M.D.F. McInnes, D. Moher, B.D. Thombs, T.A. McGrath, P.M. Bossuyt, T. Clifford, J.F. Cohen, J.J. Deeks, C. Gatsonis, L. Hooft, H.A. Hunt, C.J. Hyde, D.A. Korevaar, M.M.G. Leeflang, P. Macaskill, J.B. Reitsma, R. Rodin, A.W.S. Rutjes, J.P. Salameh, A. Stevens, Y. Takwoingi, M. Tonelli, L. Weeks, P. Whiting, B.H. Willis, Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 319(4), 388–396 (2018). https://doi.org/10.1001/jama.2017.19163 Google Scholar
- 16.P.F. Whiting, A.W. Rutjes, M.E. Westwood, S. Mallett, J.J. Deeks, J.B. Reitsma, M.M. Leeflang, J.A. Sterne, P.M. Bossuyt, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155(8), 529–536 (2011). https://doi.org/10.7326/0003-4819-155-8-201110180-00009 Google Scholar
- 19.N. Sampathirao, S. Basu, MIB-1 index-stratified assessment of dual-tracer PET/CT with (68)Ga-DOTATATE and (18)F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting. J. Nucl. Med. Technol. 45(1), 34–41 (2017). https://doi.org/10.2967/jnmt.116.185777 Google Scholar
- 20.Y. Menda, T.M. O’Dorisio, J.R. Howe, M. Schultz, J.S. Dillon, D. Dick, G.L. Watkins, T. Ginader, D.L. Bushnell, J.J. Sunderland, G.K.D. Zamba, M. Graham, M.S. O’Dorisio, Localization of unknown primary site with (68)Ga-DOTATOC PET/CT in patients with metastatic neuroendocrine tumor. J. Nucl. Med. 58(7), 1054–1057 (2017). https://doi.org/10.2967/jnumed.116.180984 Google Scholar
- 21.P.M. Kazmierczak, A. Rominger, V. Wenter, C. Spitzweg, C. Auernhammer, M.K. Angele, C. Rist, C.C. Cyran, The added value of (68)Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. Eur. Radiol. 27(4), 1676–1684 (2017). https://doi.org/10.1007/s00330-016-4475-3 Google Scholar
- 22.S.M. Sadowski, V. Neychev, C. Millo, J. Shih, N. Nilubol, P. Herscovitch, K. Pacak, S.J. Marx, E. Kebebew, Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J. Clin. Oncol. 34(6), 588–596 (2016). https://doi.org/10.1200/jco.2015.64.0987 Google Scholar
- 23.A. Pruthi, P. Pankaj, R. Verma, A. Jain, E.S. Belho, H. Mahajan, Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J. Gastrointest. Oncol. 7(3), 449–461 (2016). https://doi.org/10.21037/jgo.2016.01.06 Google Scholar
- 24.Y. Nakamoto, K. Sano, T. Ishimori, M. Ueda, T. Temma, H. Saji, K. Togashi, Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors. Ann. Nucl. Med. 29(6), 512–518 (2015). https://doi.org/10.1007/s12149-015-0973-7 Google Scholar
- 26.N.F. Schreiter, A.M. Bartels, V. Froeling, I. Steffen, U.F. Pape, A. Beck, B. Hamm, W. Brenner, R. Rottgen, Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol. Oncol. 48(4), 339–347 (2014). https://doi.org/10.2478/raon-2014-0018 Google Scholar
- 29.G. Lapinska, M. Bryszewska, A. Fijolek-Warszewska, I. Kozlowicz-Gudzinska, P. Ochman, A. Sackiewicz-Slaby, The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl. Med. Rev. Cent. East. Eur. 14(1), 16–20 (2011)Google Scholar
- 31.S. Gabriel, P. Garrigue, L. Dahan, F. Castinetti, F. Sebag, K. Baumstark, C. Archange, A. Jha, K. Pacak, B. Guillet, D. Taieb, Prospective evaluation of (68) Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clin. Endocrinol. (2018). https://doi.org/10.1111/cen.13745
- 32.S.H. Chen, Y.C. Chang, T.L. Hwang, J.S. Chen, W.C. Chou, C.H. Hsieh, T.S. Yeh, J.T. Hsu, C.N. Yeh, J.H. Tseng, T.C. Chen, T.C. Yen, 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan. J. Formos. Med. Assoc. 117(6), 480–487 (2018). https://doi.org/10.1016/j.jfma.2017.07.007 Google Scholar
- 33.A. Tirosh, G.Z. Papadakis, C. Millo, S.M. Sadowski, P. Herscovitch, K. Pacak, S.J. Marx, L. Yang, P. Nockel, J. Shell, P. Green, X.M. Keutgen, D. Patel, N. Nilubol, E. Kebebew, Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-Avid tumor volume measurements. Eur. J. Endocrinol. 176(5), 575–582 (2017). https://doi.org/10.1530/eje-16-1079 Google Scholar
- 34.P. Thapa, R. Ranade, V. Ostwal, S.V. Shrikhande, M. Goel, S. Basu, Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Nucl. Med. Commun. 37(10), 1030–1037 (2016). https://doi.org/10.1097/mnm.0000000000000547 Google Scholar
- 35.J. Kunikowska, D. Pawlak, A. Kolasa, R. Mikolajczak, L. Krolicki, A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Clin. Nucl. Med. 39(10), 855–861 (2014). https://doi.org/10.1097/rlu.0000000000000533 Google Scholar
- 36.M. Pavel, D. O’Toole, F. Costa, J. Capdevila, D. Gross, R. Kianmanesh, E. Krenning, U. Knigge, R. Salazar, U.F. Pape, K. Oberg, ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2), 172–185 (2016). https://doi.org/10.1159/000443167 Google Scholar
- 37.A. Polish, M.T. Vergo, M. Agulnik, Management of neuroendocrine tumors of unknown origin. J. Natl. Compr. Cancer Netw. 9(12), 1397–1402 (2011). quiz 1403Google Scholar
- 38.M.H. Shah, W.S. Goldner, T.R. Halfdanarson, E. Bergsland, J.D. Berlin, D. Halperin, J. Chan, M.H. Kulke, A.B. Benson 3rd, L.S. Blaszkowsky, J. Eads, P.F. Engstrom, P. Fanta, T. Giordano, J. He, M.J. Heslin, G.P. Kalemkerian, F. Kandeel, S.A. Khan, W.Z. Kidwai, P.L. Kunz, B.W. Kuvshinoff 2nd, C. Lieu, V.G. Pillarisetty, L. Saltz, J.A. Sosa, J.R. Strosberg, C.A. Sussman, N.A. Trikalinos, N.A. Uboha, J. Whisenant, T. Wong, J.C. Yao, J.L. Burns, N. Ogba, G. Zuccarino-Catania, NCCN Guidelines insights: neuroendocrine and adrenal tumors, Version 2.2018. J. Natl. Compr. Cancer Netw. 16(6), 693–702 (2018). https://doi.org/10.6004/jnccn.2018.0056 Google Scholar
- 39.V. Rufini, G. Treglia, F. Montravers, A. Giordano, Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin. Transl. Imaging 1, 111–122 (2013)Google Scholar
- 40.A. Imperiale, E. Rust, S. Gabriel, J. Detour, B. Goichot, B. Duclos, J.E. Kurtz, P. Bachellier, I.J. Namer, D. Taieb, 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J. Nucl. Med. 55(3), 367–372 (2014). https://doi.org/10.2967/jnumed.113.126896 Google Scholar